188 related articles for article (PubMed ID: 37429175)
21. Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas.
Wege H; Schulze K; von Felden J; Calderaro J; Reig M;
Eur J Med Genet; 2021 Nov; 64(11):104313. PubMed ID: 34418585
[TBL] [Abstract][Full Text] [Related]
22. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
23. Fibrolamellar hepatocellular carcinoma at a tertiary centre in South Africa: a case series.
Bhaijee F; Locketz ML; Krige JE
S Afr J Surg; 2009 Nov; 47(4):108-11. PubMed ID: 20141066
[TBL] [Abstract][Full Text] [Related]
24. Fibrolamellar hepatocellular carcinoma.
Liu S; Chan KW; Wang B; Qiao L
Am J Gastroenterol; 2009 Oct; 104(10):2617-24; quiz 2625. PubMed ID: 19638962
[TBL] [Abstract][Full Text] [Related]
25. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
26. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
27. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
28. Alternative lengthening of telomeres in primary hepatic neoplasms.
Yasir S; Thompson S; Chen ZE; Knudson R; Knutson D; Kloft-Nelson S; Graham RP; Jain D; Simon SM; Wu TT; Torbenson M
Hum Pathol; 2023 Jan; 131():79-86. PubMed ID: 36370823
[TBL] [Abstract][Full Text] [Related]
29. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.
Ng IO; Shek TW; Nicholls J; Ma LT
J Gastroenterol Hepatol; 1998 Jan; 13(1):34-40. PubMed ID: 9737569
[TBL] [Abstract][Full Text] [Related]
30. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract][Full Text] [Related]
31. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D; Villanueva A; Friedman SL; Llovet JM
Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
[TBL] [Abstract][Full Text] [Related]
32. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
[TBL] [Abstract][Full Text] [Related]
33. The prognosis of fibrolamellar carcinoma versus conventional hepatocellular carcinoma: a study based on propensity score matching.
Qiu S; Chen R; Hu J; Han T
Scand J Gastroenterol; 2023; 58(11):1351-1358. PubMed ID: 37353942
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma with both fibrolamellar and classical components: an unusual morphological pattern.
Castro-Villabón D; Barrera-Herrera LE; Rodríguez-Urrego PA; Hudacko R; Vera A; Álvarez J; Andrade R; López R
Case Rep Pathol; 2015; 2015():609780. PubMed ID: 25815229
[TBL] [Abstract][Full Text] [Related]
35. Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management.
Aziz H; Brown ZJ; Panid Madani S; Kamel IR; Pawlik TM
J Am Coll Surg; 2023 Feb; 236(2):399-410. PubMed ID: 36648268
[TBL] [Abstract][Full Text] [Related]
36. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
Kim J; Kim Y; Lee B
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
[TBL] [Abstract][Full Text] [Related]
37. [Primary Liver Cancers - Hepatocellular Carcinoma and Cholangiocarcinoma].
Soysal SD; Kollmar O
Ther Umsch; 2021; 78(10):585-588. PubMed ID: 34844438
[TBL] [Abstract][Full Text] [Related]
38. Update on the pathology of liver neoplasms.
Matsukuma KE; Yeh MM
Ann Diagn Pathol; 2019 Feb; 38():126-137. PubMed ID: 30597357
[TBL] [Abstract][Full Text] [Related]
39. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
